Shockwave Medical Debuts Enhanced Catheter at TCT 2023, Announces Clinical Research Validation
October 30, 2023 — Shockwave Medical, Inc., which develops technologies for the treatment of cardiovascular disease, has announced the planned United States introduction of the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) catheter, following approval by the U.S. Food and Drug Administration. The enhanced C2+ catheter made its U.S. debut at the Transcatheter Cardiovascular Therapeutics annual scientific symposium of the Cardiovascular Research Foundation (CRF), TCT 2023, held Oct. 23-26 in San Francisco, CA. The full commercial launch is planned for the beginning of November. “The enhancements of Shockwave C2+ will be an added benefit of IVL for optimally treating complex calcium, including more diffuse disease, as well as nodular and thick, eccentric calcium,” said Richard Shlofmitz, MD, Chairman, Department of Cardiology, St. Francis Hospital in Roslyn, New York, who performed the first U.S. commercial case with Shockwave C2+. He added, “When additional pulses are added to t